|  |  |  |  |
| --- | --- | --- | --- |
|  | Our cohort (All patients) | EVEREST (Organic and Functional MR) [20] | COAPT (Functional MR) [21] |
| Diabetes | 43.5% | 41% | 35.1% |
| Ischemic heart disease | 46.1% | 84.2% | 60.9% |
| Atrial fibrillation | 62.8% | 61.6% | 57.3% |
| Chronic obstructive pulmonary disease | 15.3% | 34.6% | 23.5% |
| Chronic Kidney disease | 42.3% | 23.1% | 71.6% |
| NYHA 3 or 4 | 65.4% | 89.8% | 57.0% |
| Prior heart failure hospitalization | 69.2% | 65.0% | 58.3% |
| EROA (cm2) | 0.37 (0.30-0.40) | - | 0.41±0.15 |
| LVEF (%) | 50.0 [36.0;60.0] | 54.4 ± 13.7 | 31.3 ± 9.1 |
| LVEDV (ml) | 120 [90.8;151] | 166 ± 51 | 194.4±69.2 |
| LVESV (ml) | 61.0 [38.0;91.0] | 80 ± 43 | 135.5 ± 56.1 |
| LVEDD (mm) |  54.9±8.87 | - | 62 ± 7 |
| LVESV (mm) | 38.0 [31.0;49.0]  | 39 ± 11 | 53 ± 9 |
| PASP (mmHg) | 48.5 [38.8;66.0] | - | 44.0±13.4 |
|  |  |  |  |

**Table S1**. Baseline characteristics of our cohort, EVEREST and COAPT patients. *MR, Mitral Regurgitation; NYHA, New York heart association; EROA, effective regurgitant orifice area; LVEF, left ventricular ejection fraction; LVED, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; LVEDD, left ventricular end-diastolic diameter; LVESD, left ventricular end-systolic diameter; PASP, pulmonary artery systolic pressure.*